Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT05693090. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 1 Study of Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer
Study identification
- NCT ID
- NCT05693090
- Recruitment status
- Withdrawn
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Kura Oncology, Inc.
- Industry
- Enrollment
- Not listed
Conditions and interventions
Conditions
Interventions
- Osimertinib Drug
- Tipifarnib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 31, 2023
- Primary completion
- Jul 26, 2027
- Completion
- Jul 26, 2027
- Last update posted
- Mar 5, 2023
2023 – 2027
United States locations
- U.S. sites
- 2
- U.S. states
- 2
- U.S. cities
- 2
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Providence Medical Group | Santa Rosa | California | 95403 | — |
| The Valley Hospital | Ridgewood | New Jersey | 07450 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05693090, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 5, 2023 · Synced May 14, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05693090 live on ClinicalTrials.gov.